Status:

RECRUITING

A Prospective Study Evaluating the Impact of Conservative Management on Retained Products of Conception and EMV

Lead Sponsor:

Fu Xing Hospital, Capital Medical University

Conditions:

Retained Products of Conception

Miscarriage

Eligibility:

FEMALE

Brief Summary

The goal of this observational study is to learn about the therapeutic effects of the conservative treatment approach on pepole with retained products of conception (RPOC) and Enhanced myometrial vasc...

Eligibility Criteria

Inclusion Criteria:

  • Recent history of miscarriage or delivery (within the past 8 weeks)
  • Strong willingness to undergo conservative management
  • Hemodynamically stable
  • Signed informed consent form

Exclusion Criteria:

  • Heavy vaginal bleeding (requiring immediate surgical intervention)
  • Active pelvic or systemic infection (e.g., fever >38°C, elevated CRP/WBC)
  • Severe dysfunction of vital organs (heart, liver, or kidney)
  • Known drug allergies or contraindications to proposed medications (e.g., misoprostol intolerance)
  • Suspected ectopic pregnancy or gestational trophoblastic disease (confirmed by ultrasound or β-hCG levels)
  • Placenta accreta spectrum disorders diagnosed during current pregnancy
  • History of uterine artery embolization

Key Trial Info

Start Date :

October 23 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 30 2026

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT06862089

Start Date

October 23 2024

End Date

December 30 2026

Last Update

June 15 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hysteroscopy Center, Fuxing Hospital, Capital Medical University

Beijing, China, 100086